secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019739
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Q1 revenue down 10.5% to $3.4M, operating expenses cut 22%; Medicare reimbursement approved for CARE devices
--------------------------------------------------------------------------------

- Q1 revenue $3.4M vs $3.8M YoY; gross margin 57% vs 61%.
- Operating expenses down 22% YoY ($1.6M reduction); operating loss reduced 24% YoY.
- Cash $2.6M at March 31; Feb 2024 warrant exercise raised ~$4.0M from 980,393 shares.
- April 2024: received Medicare reimbursement approval for CARE oral devices, enabling coverage for beneficiaries.
- Management targets cash flow positive from operations by end of 2024 or Q1 2025, assuming revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/0001493152-24-019739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer